Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774019 · ClinicalTrials.gov registry record · NA
Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 284
- Enrollment target
NCT01774019 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 284 participants.
The verdict
NCT01774019, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 284 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that preoperative biliary drainage using self-expanding metal stents (SEMS) does not negatively impact overall surgical outcomes in patients undergoing pancreaticoduodenectomy for treatment of pancreatic or periampullary cancer.
Interventions
- DEVICE WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2013-02-20 |
| Est. Completion | 2021-12-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01774019
The ClinicalTrials.gov registry entry for NCT01774019 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WallFlex™ Biliary RX Fully Covered/Uncovered Stent System is the first listed.
NCT01774019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01774019 about?
NCT01774019 is a clinical study titled "Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer". The purpose of this study is to demonstrate that preoperative biliary drainage using self-expanding metal stents (SEMS) does not negatively impact overall surgical outcomes in patients undergoing pancreaticoduodenectomy for treatment of pancreatic or periampullary cancer.
What is the current status of trial NCT01774019?
This trial is currently completed. It is a NA study. The enrollment target is 284 participants. The study started on 2013-02-20. Estimated completion is 2021-12-13.
What interventions are being tested in trial NCT01774019?
The interventions under investigation include: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System (DEVICE).
Who is sponsoring clinical trial NCT01774019?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.